Search

Kyra D Zens

from New York, NY
Age ~40
Get Report
Also known as:
Kyra D Emory
Related to:
Ruth G Sanders, 80Allan D Sanders, 84J Emory Killian, 38Bruce C Emory, 67Robert R Bear, 64Axel R Bear, 99Richard Zens, 47Emory Killian, 38Terrie L Bear, 62Frank A Sanders, 62Bruce C Emory, 65
Connected to:
Darren Zens, 41Jeremy P Zens, 49April Zensen, 42Farah Zensen, 47Larry J Zent, 46Logan Zent, 42Pat Zent, 102Patrick A Zent, 62Stacey Zent, 53Vickie L Zent, 62

Kyra Zens Phones & Addresses

  • New York, NY
  • 77511 N Overlook Dr, Benton City, WA 99320
  • Mountain View, CA
  • San Mateo, CA
  • Richland, WA
  • Pullman, WA

Publications

Us Patents

Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses Thereof

View page
US Patent:
20110150892, Jun 23, 2011
Filed:
Aug 11, 2009
Appl. No.:
13/058492
Inventors:
Kent B. Thudium - Oakland CA, US
Mark Selby - San Francisco CA, US
Kyra D. Zens - San Mateo CA, US
Mark Yamanaka - Pleasanton CA, US
Alan J. Korman - Piedmont CA, US
Heidi N. LeBlanc - Mountain View CA, US
International Classification:
A61K 39/395
C12P 21/08
C12N 5/10
C12N 5/02
C12N 15/63
C07K 16/00
C07H 21/04
A61P 37/00
A61P 35/00
A61P 31/12
US Classification:
4241421, 4241781, 435 696, 435325, 435375, 4353201, 53038815, 536 2353
Abstract:
The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen- specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti- LAG-3 antibody is co-administered with at least one additional immuno stimulatory antibody, is also provided.

Antibodies To Bone Morphogenic Proteins And Receptors Therefor And Methods For Their Use

View page
US Patent:
20110182904, Jul 28, 2011
Filed:
Sep 5, 2007
Appl. No.:
12/440000
Inventors:
Deborah Zimmerman - Oakland CA, US
Mark Selby - San Francisco CA, US
Mohan Srinivasan - San Jose CA, US
Alasdair Bell - Mountain View CA, US
Sujata Singh - Saratoga CA, US
Richard Theolis - Santa Cruz CA, US
Heidi N. Leblanc - Mountain View CA, US
Kyra D. Zens - San Mateo CA, US
Timothy William Sproul - Livermore CA, US
International Classification:
A61K 39/395
C07K 16/22
A61P 19/08
A61P 35/00
C12N 15/13
C12N 15/63
C12N 5/00
C12P 21/08
US Classification:
4241451, 53038823, 5303873, 5303911, 5303917, 5303913, 536 2353, 4353201, 435325, 435 696, 800 4
Abstract:
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, which specifically bind to BMP2, BMP4, BMPR1A, BMPR1B, ACTR1, and/or BMPR2 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Also provided are immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention and, optionally, one or more additional therapeutic. The invention also provides methods for treating diseases associated with abnormal bone formation and ossification mediated by BMP2, BMP4, BMPR1A, BMPR1B, ACTR15 and/or BMPR2.

Human Antibodies That Bind Cd22 And Uses Thereof

View page
US Patent:
20130230530, Sep 5, 2013
Filed:
Feb 20, 2013
Appl. No.:
13/772063
Inventors:
Alison Witte - Scotts Valley CA, US
Heidi N. Leblanc - Mountain View CA, US
Richard Theolis - Santa Cruz CA, US
Asna Masood - Saratoga CA, US
Mark Yamanaka - Pleasanton CA, US
Kyra D. Zens - San Mateo CA, US
Sarah R. Reed - Sanat Cruz CA, US
Tim Sproul - Livermore CA, US
David Passmore - Mountain View CA, US
Dawn M. Tanamachi - San Carlos CA, US
Kristopher Toy - San Jose CA, US
Assignee:
Medarex, Inc. - Princeton NJ
International Classification:
C07K 16/30
A61K 45/06
A61K 39/395
US Classification:
4241391, 435375, 4241781, 4241791
Abstract:
The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

Human Antibodies That Bind Cd22 And Uses Thereof

View page
US Patent:
8481683, Jul 9, 2013
Filed:
Nov 30, 2007
Appl. No.:
12/517183
Inventors:
David John King - Solana Beach CA, US
Alison Witte - Scotts Valley CA, US
Heidi N. LeBlanc - Mountain View CA, US
Richard Theolis - Santa Cruz CA, US
Asna Masood - Saratoga CA, US
Mark Yamanaka - Pleasanton CA, US
Kyra D. Zens - San Mateo CA, US
Sarah R. Reed - Santa Cruz CA, US
Tim Sproul - Livermore CA, US
David Passmore - Mountain View CA, US
Dawn M. Tanamachi - San Carlos CA, US
Kristopher Toy - San Jose CA, US
Assignee:
Medarex, Inc. - Princeton NJ
International Classification:
C12P 21/08
C07K 16/00
A61K 39/395
A61K 39/40
C07K 1/00
US Classification:
5303871, 5303873, 5303877, 5303881, 53038815, 53038822, 5303911, 5303913, 4241301, 4241331, 4241381, 4241411, 4241421, 4241431, 4241441, 4241521, 4241531, 4241551, 4241561, 4241781
Abstract:
The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3), And Uses Thereof

View page
US Patent:
20220204612, Jun 30, 2022
Filed:
Dec 7, 2021
Appl. No.:
17/544542
Inventors:
- Princeton NJ, US
Mark J. SELBY - San Francisco CA, US
Kyra D. ZENS - San Mateo CA, US
Mark YAMANAKA - Pleasanton CA, US
Alan J. KORMAN - Piedmont CA, US
Heidi N. LEBLANC - Mountain View CA, US
International Classification:
C07K 16/28
Abstract:
The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.

Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3), And Uses Thereof

View page
US Patent:
20220195040, Jun 23, 2022
Filed:
Dec 7, 2021
Appl. No.:
17/544534
Inventors:
- Princeton NJ, US
Mark J. SELBY - San Francisco CA, US
Kyra D. ZENS - San Mateo CA, US
Mark YAMANAKA - Pleasanton CA, US
Alan J. KORMAN - Piedmont CA, US
Heidi N. LEBLANC - Mountain View CA, US
International Classification:
C07K 16/28
Abstract:
The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to WIC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.

Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3), And Uses Thereof

View page
US Patent:
20210261660, Aug 26, 2021
Filed:
Apr 9, 2021
Appl. No.:
17/226595
Inventors:
- Princeton NJ, US
Mark J. SELBY - San Francisco CA, US
Kyra D. ZENS - San Mateo CA, US
Mark YAMANAKA - Pleasanton CA, US
Alan J. KORMAN - Piedmont CA, US
Heidi N. LEBLANC - Mountain View CA, US
International Classification:
C07K 16/28
Abstract:
The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.

Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3), And Uses Thereof

View page
US Patent:
20210261661, Aug 26, 2021
Filed:
Apr 9, 2021
Appl. No.:
17/226609
Inventors:
- Princeton NJ, US
Mark J. SELBY - San Francisco CA, US
Kyra D. ZENS - San Mateo CA, US
Mark YAMANAKA - Pleasanton CA, US
Alan J. KORMAN - Piedmont CA, US
Heidi N. LEBLANC - Mountain View CA, US
International Classification:
C07K 16/28
Abstract:
The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to WIC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.
Control profile
Kyra D Zens from New York, NY, age ~40 Get Report